Brokers Issue Forecasts for Pharma-Bio Serv FY2026 Earnings

Pharma-Bio Serv Inc. (OTCMKTS:PBSV) – Equities research analysts at Zacks Research dropped their FY2026 EPS estimates for shares of Pharma-Bio Serv in a report issued on Tuesday, June 16th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of $0.07 per share for the year, down from their prior forecast of $0.09. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.09 per share. Zacks Research also issued estimates for Pharma-Bio Serv’s Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.02 EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at $0.04 EPS and FY2027 earnings at $0.11 EPS.

Pharma-Bio Serv Price Performance

Shares of PBSV stock opened at $0.57 on Thursday. The business has a 50-day moving average price of $0.53 and a two-hundred day moving average price of $0.54. Pharma-Bio Serv has a 12-month low of $0.43 and a 12-month high of $1.36.

Pharma-Bio Serv (OTCMKTS:PBSV) last posted its quarterly earnings data on Monday, June 15th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Pharma-Bio Serv had a net margin of 0.68% and a return on equity of 0.56%. The company had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.70 million.

Pharma-Bio Serv Company Profile

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc was founded in 1993 and is headquartered in Dorado, Puerto Rico.